Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$21.22 - $32.66 $969,435 - $1.49 Million
-45,685 Reduced 83.07%
9,314 $218,000
Q1 2024

May 15, 2024

BUY
$23.46 - $45.07 $436,848 - $839,248
18,621 Added 51.19%
54,999 $1.82 Million
Q4 2023

Feb 14, 2024

BUY
$17.69 - $30.76 $643,526 - $1.12 Million
36,378 New
36,378 $990,000
Q1 2023

May 15, 2023

BUY
$30.15 - $48.79 $598,598 - $968,676
19,854 Added 74.49%
46,509 $1.42 Million
Q4 2022

Feb 14, 2023

BUY
$36.73 - $51.6 $526,010 - $738,963
14,321 Added 116.11%
26,655 $1.04 Million
Q3 2022

Nov 14, 2022

SELL
$39.79 - $70.31 $3.13 Million - $5.52 Million
-78,564 Reduced 86.43%
12,334 $588,000
Q2 2022

Aug 15, 2022

SELL
$29.86 - $62.36 $227,563 - $475,245
-7,621 Reduced 7.74%
90,898 $3.52 Million
Q1 2022

May 16, 2022

BUY
$53.73 - $82.16 $5.29 Million - $8.09 Million
98,519 New
98,519 $5.65 Million
Q4 2021

Feb 14, 2022

SELL
$68.02 - $99.06 $2.84 Million - $4.14 Million
-41,815 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$84.37 - $133.6 $2.19 Million - $3.46 Million
25,914 Added 162.97%
41,815 $3.64 Million
Q2 2021

Aug 16, 2021

SELL
$64.12 - $128.71 $1.34 Million - $2.69 Million
-20,916 Reduced 56.81%
15,901 $2.05 Million
Q1 2021

May 17, 2021

BUY
$71.28 - $120.75 $2.62 Million - $4.45 Million
36,817 New
36,817 $2.95 Million
Q4 2020

Feb 16, 2021

SELL
$22.24 - $95.63 $350,057 - $1.51 Million
-15,740 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$19.0 - $30.57 $141,360 - $227,440
7,440 Added 89.64%
15,740 $388,000
Q2 2020

Aug 14, 2020

BUY
$15.26 - $28.66 $126,658 - $237,878
8,300 New
8,300 $232,000

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.78B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Squarepoint Ops LLC Portfolio

Follow Squarepoint Ops LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.